LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)

Journal article

Open access

Peer reviewed

A. Bullock, M. Fakih, M. Gordon, A. Tsimberidou, A. El-Khoueiry, B. Wilky, A. Pimentel, K. Margolin, D. Mahadevan, A. Balmanoukian, …

Annals of oncology, Vol.34, pp.S178-S179

2023-06

Files and links (1)

url

https://doi.org/10.1016/j.annonc.2023.04.014View

Published (Version of record) Open

2 Record Views

Title: LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
Creators: A. Bullock - Beth Israel Deaconess Medical Center
M. Fakih - City Of Hope National Medical Center
M. Gordon - HonorHealth
A. Tsimberidou - The University of Texas MD Anderson Cancer Center
A. El-Khoueiry - USC Norris Comprehensive Cancer Center
B. Wilky - University of Colorado Cancer Center
A. Pimentel - Sylvester Comprehensive Cancer Center
K. Margolin - Saint John's Health Center
D. Mahadevan - The University of Texas Health Science Center at San Antonio
A. Balmanoukian - Angeles Clinic and Research Institute
R. Sanborn - Providence Portland Medical Center
G. Schwartz - Columbia University Irving Medical Center
G. Abou-Alfa - Cornell University
B. Bockorny - Beth Israel Deaconess Medical Center
J. Moser - HonorHealth
S. Sharma - HonorHealth
J. Grossman - Agenus
K. Rosenthal - Agenus
S. O'Day - Agenus
H. Lenz - USC Norris Comprehensive Cancer Center
B. Schlechter - Dana-Farber Cancer Institute
Publication Details: Annals of oncology, Vol.34, pp.S178-S179
Publisher: Elsevier Ltd; AMSTERDAM
Number of pages: 2
Grant note: Agenus Inc.
Agenus Inc.
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991032860902802976